Gastroesophageal reflux disease (GERD) can significantly impair health-related quality of life (QOL). In their study, F. Pace, MD, and colleagues assessed the effects of esomeprazole (a proton pump inhibitor) therapy on QOL in patients with GERD (n = 6017). Upon enrollment, patients received esomeprazole (40 mg/day) acutely for 4 weeks. If this treatment was successful, they were randomly assigned to 2 maintenance esomeprazole treatment strategies: continuous (20 mg/day) or on demand (for 6 months). QOL was measured at baseline by the generic Short-Form 36 Questionnaire and by a disease-specific instrument, QOL in Reflux and Dyspepsia (QOLRAD).
After the acute treatment phase, all QOLRAD dimensions showed statistically significant (P < .0001) and clinically meaningful improvement. There was a statistically significant but small difference in QOLRAD scores at the end of the maintenance phase in favor of the continuous versus the on-demand regimen. Improved QOL was maintained during the 6-month followup, with patients favoring the continuous- treatment strategy, according to a study in Alimentary Pharmacology & Therapeutics (September 2005).
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs